Cancer therapy and prevention by green tea: role of ornithine decarboxylase

被引:54
|
作者
Bachrach, U [1 ]
Wang, YC [1 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel
关键词
amino acids; green tea; polyphenols; (-)-epigallocatechin-3-gallate (GCG); polyamines; ornithine decarboxylase (ODC); cancer prevention; cancer therapy;
D O I
10.1007/s726-002-8197-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Green tea which is widely consumed in China, Japan and India, contains polyphenolic compounds, which account for 30% of the dry weight of the leaves. Most of the polyphenols are flavanols, of which (-)-epigallocatechin-3-gallate (EGCG) is most abundant. Epidemiological studies revealed that the incidences of stomach and prostate cancers are the lowest in the world among a population that consumes green tea on a regular basis. It has also been reported that the quantity of green tea consumed, plays an important role in reducing cancer risk and in delaying cancer outbreak and recurrence. Various systems were used to confirm anti-cancer activities of green tea and/or EGCG. These included experimental animals in which cancer was induced chemically. Cultured cells transformed chemically or by oncogenes were also used. These studies clearly demonstrated that green tea or EGCG have anticancer and cancer preventive properties. The mechanisms of these activities have also been studied in details. It has been shown that green tea and its active components interfere with signal transduction pathways. Thus the activities of various protein kinases are inhibited, the expression of nuclear proto-oncogenes declines and the activity of ornithine decarboxylase (ODC) is reduced. ODC, which catalyzes the rate-limiting step in the biosynthesis of polyamines is closely linked with cellular proliferation and carcinogenesis. Inhibitors of ODC, like alpha-difluoromethylornithine (DFMO) have long been used for cancer prevention and therapy. It has been suggested that polyamine depletion by green tea could offer one explanation for its anti-cancer activities.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [31] Green tea and its isolated constituents in cancer prevention
    Sapone, A
    Canistro, D
    Broccoli, M
    Pozzetti, L
    Affatato, A
    Vangelisti, S
    Biagi, GL
    Sblendorio, V
    Paolini, M
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 578 (1-2) : 434 - 435
  • [32] Green tea for the prevention of cancer: evidence of field epidemiology
    Zhang, Min
    Li, Lin
    Liu, Ping
    Holman, C. D'Arcy J.
    FUNCTIONAL FOODS IN HEALTH AND DISEASE, 2012, 2 (10): : 339 - 349
  • [33] Green tea compounds in breast cancer prevention and treatment
    Li, Min-Jing
    Yin, Yan-Cun
    Wang, Jiao
    Jiang, Yang-Fu
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (03): : 520 - 528
  • [34] Epigenetic Mechanisms for Green Tea in Prevention of Colon Cancer
    Wargovich, M. J.
    Morris, J.
    Moseley, V.
    Weber, R.
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2011, 47 : S15 - S15
  • [35] Green tea catechin as a chemical chaperone in cancer prevention
    Kuzuhara, Takashi
    Suganuma, Masami
    Fujiki, Hirota
    CANCER LETTERS, 2008, 261 (01) : 12 - 20
  • [36] Fish oil, green tea, and prostate cancer prevention
    Shannon, J.
    Lieberman, S.
    Maxcy, C.
    Thuillier, P.
    Peters, L.
    Garzotto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Multitargeted therapy of cancer by green tea polyphenols
    Khan, Naghma
    Mukhtar, Hasan
    CANCER LETTERS, 2008, 269 (02) : 269 - 280
  • [38] A ROLE OF ORNITHINE DECARBOXYLASE IN INSULIN-SECRETION
    HADDOX, MK
    TIPNIS, S
    KAO, YCJ
    KNUTSON, VP
    GASTROENTEROLOGY, 1993, 104 (04) : A829 - A829
  • [39] The role of antioxidant versus pro-oxidant effects of green tea polyphenols in cancer prevention
    Forester, Sarah C.
    Lambert, Joshua D.
    MOLECULAR NUTRITION & FOOD RESEARCH, 2011, 55 (06) : 844 - 854
  • [40] ROLE OF ORNITHINE DECARBOXYLASE IN COMPENSATORY LUNG GROWTH
    THET, LA
    CLINICAL RESEARCH, 1982, 30 (02): : A438 - A438